Work

Ipilimumab-Induced Adrenalitis

Year: 2015

Type: article

Abstract: Ipilimumab is a monoclonal antibody against the inhibitory CTLA-4 receptor expressed on T cells. It provokes an upregulation of the immune system. This substance was approved by the US Food and Drug Administration in 2011 and is since increasingly used as a targeted therapeutic approach for metastasized melanoma. Ipilimumab is known to cause neuroendocrine disorders, such as hypophysitis and adrenal insufficiency. Our case of a 79-year-old patient represents an important imaging pitfall. Imaging findings of newly symmetrically and smoothly enlarged, hypermetabolic adrenal glands in the setting of previous ipilimumab therapy represent drug-induced adrenalitis and not metastatic disease.

Source: Clinical Nuclear Medicine

DOI: 10.1097/rlu.0000000000000887

Authors: Sara Bacanovic, Irene A. Burger, Paul Stolzmann, Jürg Hafner, Martin W. Huellner

Institutions: University of Zurich, University Hospital Zurich

Language: English

Topic: Adrenal Hormones and Disorders

Subfield: Endocrinology, Diabetes and Metabolism

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W874828184